Parmax Pharma Hits 52-Week Low, Receives 'Strong Sell' Rating from MarketsMOJO

Parmax Pharma, a microcap pharmaceutical company, has recently hit a 52-week low on March 13, 2024. The stock has been given a 'Strong Sell' rating by MarketsMOJO, indicating a negative outlook for the company.

The stock price of Parmax Pharma has reached a new low of Rs.24.18, as reported today. However, the company has outperformed the pharma sector by 5.51% in today's trading session. This could be seen as a positive sign for the company, as it has gained after four consecutive days of falling.

In terms of moving averages, Parmax Pharma is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This suggests a downward trend in the stock's performance.

The pharma sector as a whole has also seen a decline of -2.21%, indicating a broader trend in the industry. However, Parmax Pharma's 1-year performance has been -12.30%, while the Sensex has shown a growth of 25.19%. This shows that the company has not been able to keep up with the overall market performance.

Investors should be cautious when considering Parmax Pharma as an investment option, as the company's stock has been on a downward trend and has received a negative rating from MarketsMOJO. It is important to do thorough research and consider all factors before making any investment decisions.